BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26727705)

  • 1. Measurement of urinary copper excretion after 48-h d-penicillamine cessation as a compliance assessment in Wilson's disease.
    Dzieżyc K; Litwin T; Chabik G; Członkowska A
    Funct Neurol; 2015; 30(4):264-8. PubMed ID: 26727705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pattern of urinary copper excretion and its response to treatment in patients with Wilson's disease.
    Walshe JM
    QJM; 2011 Sep; 104(9):775-8. PubMed ID: 21622540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance zinc therapy after initial penicillamine chelation to treat symptomatic hepatic Wilson's disease in resource constrained setting.
    Gupta P; Choksi M; Goel A; Zachariah U; Sajith KG; Ramachandran J; Chandy G; Kurian G; Rebekah G; Eapen CE
    Indian J Gastroenterol; 2018 Jan; 37(1):31-38. PubMed ID: 29457214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compliant treatment with anti-copper agents prevents clinically overt Wilson's disease in pre-symptomatic patients.
    Dzieżyc K; Karliński M; Litwin T; Członkowska A
    Eur J Neurol; 2014 Feb; 21(2):332-7. PubMed ID: 24313946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary copper excretion before and after oral intake of d-penicillamine in parents of patients with Wilson's disease.
    Vieira J; Oliveira PV; Juliano Y; Warde KR; Deguti MM; Barbosa ER; Carrilho FJ; Cancado EL
    Dig Liver Dis; 2012 Apr; 44(4):323-7. PubMed ID: 22169274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of chelation treatment with typical penicillamine in cross combination with DMPS repeatedly for Wilson's disease.
    Xu SQ; Li XF; Zhu HY; Liu Y; Fang F; Chen L
    J Huazhong Univ Sci Technolog Med Sci; 2013 Oct; 33(5):743-747. PubMed ID: 24142730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined sodium Dimercaptopropanesulfonate and zinc versus D-penicillamine as first-line therapy for neurological Wilson's disease.
    Zhang J; Xiao L; Yang W
    BMC Neurol; 2020 Jun; 20(1):255. PubMed ID: 32593295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Appropriate administration schedule of D-penicillamine for pediatric Wilson's disease patients based on urinary copper excretion].
    Fukuoka N; Morita S; Hamatani S; Okada H; Kondoh M; Imai T; Ohnishi S; Itoh S
    Yakugaku Zasshi; 2002 Aug; 122(8):585-8. PubMed ID: 12187774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study.
    Merle U; Schaefer M; Ferenci P; Stremmel W
    Gut; 2007 Jan; 56(1):115-20. PubMed ID: 16709660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between striatal glucose consumption and copper excretion in patients with Wilson's disease treated with D-penicillamine.
    Hefter H; Kuwert T; Herzog H; Arendt G; Stremmel W; Feinendegen LE
    J Neurol; 1993 Nov; 241(1):49-53. PubMed ID: 8138822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wilson's disease: assessment of D-penicillamine treatment.
    Van Caillie-Bertrand M; Degenhart HJ; Luijendijk I; Bouquet J; Sinaasappel M
    Arch Dis Child; 1985 Jul; 60(7):652-5. PubMed ID: 4026361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term evaluation of urinary copper excretion and non-caeruloplasmin associated copper in Wilson disease patients under medical treatment.
    Pfeiffenberger J; Lohse CM; Gotthardt D; Rupp C; Weiler M; Teufel U; Weiss KH; Gauss A
    J Inherit Metab Dis; 2019 Mar; 42(2):371-380. PubMed ID: 30746719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations.
    Morita J; Yoshino M; Watari H; Yoshida I; Motohiro T; Yamashita F; Okano Y; Hashimoto T
    Dev Pharmacol Ther; 1992; 19(1):6-9. PubMed ID: 1307347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Copper chelation in patients with Wilson's disease. A comparison of penicillamine and triethylene tetramine dihydrochloride.
    Walshe JM
    Q J Med; 1973 Jul; 42(167):441-52. PubMed ID: 4728043
    [No Abstract]   [Full Text] [Related]  

  • 15. A clinical study of Wilson's disease: The experience of a single Egyptian Paediatric Hepatology Unit.
    El-Karaksy H; Fahmy M; El-Raziky MS; El-Hawary M; El-Sayed R; El-Koofy N; El-Mougy F; El-Hennawy A; El-Shabrawi M
    Arab J Gastroenterol; 2011 Sep; 12(3):125-30. PubMed ID: 22055589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Checking of urinary copper in patients with Wilson's disease during treatment with D-penicillamine].
    Indaco A; Pellegrino L; Campanella G
    Acta Neurol Quad (Napoli); 1979; 39():160-4. PubMed ID: 555232
    [No Abstract]   [Full Text] [Related]  

  • 17. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease.
    Martins da Costa C; Baldwin D; Portmann B; Lolin Y; Mowat AP; Mieli-Vergani G
    Hepatology; 1992 Apr; 15(4):609-15. PubMed ID: 1551638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of penicillamine-stimulated urinary copper excretion in the diagnosis of adult Wilson's disease.
    Foruny JR; Boixeda D; López-Sanroman A; Vázquez-Sequeiros E; Villafruela M; Vázquez-Romero M; Rodríguez-Gandía M; de Argila CM; Camarero C; Milicua JM
    Scand J Gastroenterol; 2008; 43(5):597-603. PubMed ID: 18415754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Late presentation of Wilson's disease].
    Santander Vaquero C
    Rev Esp Enferm Dig; 2002 Aug; 94(8):502-3. PubMed ID: 12486857
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pathogenesis and treatment of Wilson's disease].
    Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
    Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.